DUBLIN--(BUSINESS WIRE)--The "2018 Intermittent Claudication Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Intermittent Claudication Market" report has been added to ResearchAndMarkets.com's offering.
An estimated 40 million people suffer from Intermittent Claudication disease worldwide. The disease represents Plaque deposits in primary artery limit the volume of blood supplies to legs, which results in cramps when walking. Pain is primarily observed in calves and occasionally in thighs and buttocks. Intermittent Claudication is often considered as a key symptom of the peripheral arterial disease.
To assist researchers, investors and business development managers, the publisher has come up with a comprehensive report on Intermittent Claudication pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials. Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Intermittent Claudication pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Intermittent Claudication pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Companies Mentioned
- Aldagen, Inc
- DNAVEC Corporation
- Genovate Biotechnology
- LTT Bio-Pharma Co.,Ltd.
- Novartis International AG
- Pluristem Therapeutics Inc
Key Topics Covered:
1 Table of Contents
2 Intermittent Claudication Pipeline Analysis
3 Intermittent Claudication- Company Wise Pipeline Analysis
4 Intermittent Claudication R&D Pipeline Snapshots
5 Recent Developments in Intermittent Claudication Pipeline
6 Appendix
For more information about this report visit https://www.researchandmarkets.com/research/2wwpfk/intermittent?w=4
